Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Analgesia Comparison for VATS
NCT03151434Phase 3Completed
- Sponsor
- Indiana University
- Start
- Feb 2017
- Primary completion
- Jul 2018
- Modality
- Targeted Liposomes, Orthosteric Ligands, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ropivacaine hydrochloride liposomal suspension injection, bupivacaine hydrochloride 0.75% injection and hydromorphone in postoperative pain (3 arms), sponsored by Indiana University. Primary endpoint: Visual Analog Scale Pain Score at 48 hours. Started Feb 2017; status: completed.
02
Drugs
ropivacaine hydrochloride liposomal suspension injectionbupivacaine hydrochloride 0.75% injectionhydromorphone
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03151434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03151434.